Skip to content

Pharmacodynamics and pharmacokinetics study for teicoplanin in the treatment of patients with sepsis and hypoproteinemia

Pharmacodynamics and pharmacokinetics study for teicoplanin in the treatment of patients with sepsis and hypoproteinemia

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900021160
Enrollment
Unknown
Registered
2019-01-30
Start date
2019-03-01
Completion date
Unknown
Last updated
2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoproteinemia

Interventions

Case series:Teicoplanin

Sponsors

The Affiliated Hospital of Putian University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Spesis patients who are treated with teicoplanin; 2. aged 18 years, male or female; 3. Meet the sepsis diagnose standard of The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3); 4. Patitents who are diagnosed by the clinician with Gram-positive cocci include one of the following respiratory infections, bloodstream infection, catheter-related infection, infective endocarditis, neutropenia, fever, bone and joint infection, abdominal infection, skin and soft tissue; 5. The presence of hypoproteinemia during the course of administration (serum albumin<25g/L).

Exclusion criteria

Exclusion criteria: 1. Patients who had teicoplanin Allergy or Allergy history; 2. Patients who used teicoplanin for prevention; 3. Patients who refused to participate the study, or who were unable to obtain blood samples due to unwillingness of the patient and the family of the patient; 4. Unacceptable adverse reactions or serious adverse events; 5. Patients were dead within 24 hours with the treatment of teicoplanin; 6. Patients with hypoproteinemia who were corrected before using teicoplanin.

Design outcomes

Primary

MeasureTime frame
Trough concentrations;Albumin;APACHE II Score;

Secondary

MeasureTime frame
Clinical diagnosis;leukocyte;Procalcitonin;C-reactive protein;Body Temperature;Age;Gender;Height;Weight;

Countries

China

Contacts

Public ContactQi Lin

The Affiliated Hospital of Putian University

linqitc@gmail.com+86 13959553616

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026